Search
Fadraciclib
go.drugbank.com/drugs/DB15425InvestigationalCYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).
Calcitonin porcine
go.drugbank.com/drugs/DB13189ExperimentalCalcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals. It inhibits bone resorption and lowers both serum and urinary calcium concentrations. … Human calcitonin is available only in very small quantities but has been used in some studies. The first commercially available preparation in Britain was porcine calcitonin (brand name Calcitare).
Tofimilast
go.drugbank.com/drugs/DB11681InvestigationalTofimilast has been used in trials studying the treatment of Asthma and Pulmonary Disease, Chronic Obstructive.
Tofogliflozin
go.drugbank.com/drugs/DB11824InvestigationalTofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.
IQP-0528
go.drugbank.com/drugs/DB14888InvestigationalIQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Rivenprost
go.drugbank.com/drugs/DB16315InvestigationalRivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).
DYN-101
go.drugbank.com/drugs/DB17921InvestigationalDYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.
Synonyms: 5’-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-spdA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3’Suvodirsen
go.drugbank.com/drugs/DB17940InvestigationalSuvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.
CTX110
go.drugbank.com/drugs/DB18626InvestigationalCTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Leflutrozole
go.drugbank.com/drugs/DB19047InvestigationalLeflutrozole is under investigation in clinical trial NCT02908074 (A 6 Month Safety Extension Study of MBGS205).